Yeast beta-D-glucan

DB19271InvestigationalSmall molecule

Yeast beta-D-glucan is under investigation in clinical trial NCT00632008 (Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers).

Mechanism: Pharmacologically active on Integrin beta-2, Integrin alpha-M, and C-type lectin domain family 7 member A
Curator reviewed
Also known as: Beta glucan · Beta glucan iv (saccharomyces cerevisiae) · Beta-1,3-1,6-d-glucan · Beta-1,3/1,6-D-Glucan · Glucoprime
Code names: GLYC-101 · TR-987

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

1Marketed productAcross 1 country and 1 labeller

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Yeast beta-D-glucan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.